

UTILIZATION MANAGEMENT MEDICAL POLICY

POLICY: Immunologicals – Exdensur Utilization Management Medical Policy

- Exdensur (depemokimab-ulaa subcutaneous injection – GlaxoSmithKline)

REVIEW DATE: 12/30/2025

OVERVIEW

Exdensur, an interleukin (IL)-5 antagonist monoclonal antibody, is indicated for the add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adults and pediatric patients ≥ 12 years of age.¹

Limitations of Use: Exdensur is not indicated for the relief of acute bronchospasm or status asthmaticus.

Clinical Efficacy

In the pivotal asthma studies of Exdensur, patients were generally required to have elevated eosinophils at baseline (e.g., peripheral blood eosinophil count ≥ 150 cells/microliter at screening or ≥ 300 cells/microliter at some time during the previous year). Across the studies, efficacy was assessed at Week 52.¹⁻²

Dosing Information

The recommended dosage of Exdensur for severe asthma is 100 mg once every 6 months administered by subcutaneous injection.¹ Exdensur should be administered by a healthcare provider.

Guidelines

The Global Initiative for Asthma Global Strategy for Asthma Management and Prevention (2025) proposes a step-wise approach to asthma treatment.³ Exdensur is not addressed. Other IL-5 antagonists are listed as an option for add-on therapy in patients with severe eosinophilic asthma. Severe asthma is defined as asthma that is uncontrolled despite adherence to optimized high-dose inhaled corticosteroid (ICS)/long-acting beta₂-agonist (LABA) therapy or that worsens when high-dose treatment is decreased. Higher blood eosinophil levels, higher number of severe exacerbations in the previous year, adult-onset asthma, nasal polyps, maintenance oral corticosteroid requirements, and low lung function may predict a good asthma response to IL-5 antagonist therapy.

According to the European Respiratory Society/American Thoracic Society guidelines (2014; updated in 2020), severe asthma is defined as asthma which requires treatment with a high-dose ICS in addition to a second controller medication (and/or systemic corticosteroids) to prevent it from becoming uncontrolled, or asthma which remains uncontrolled despite this therapy.^{4,5} Uncontrolled asthma is defined as asthma that worsens upon tapering of high-dose ICS or systemic corticosteroids or asthma that meets one of the following four criteria:

- 1) Poor symptom control: Asthma Control Questionnaire consistently ≥ 1.5 or Asthma Control Test < 20 ;
- 2) Frequent severe exacerbations: two or more bursts of systemic corticosteroids in the previous year;
- 3) Serious exacerbations: at least one hospitalization, intensive care unit stay, or mechanical ventilation in the previous year;
- 4) Airflow limitation: forced expiratory volume in 1 second (FEV₁) $< 80\%$ predicted after appropriate bronchodilator withholding.

POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Exdensus. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication(s). Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Exdensus as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Exdensus to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Exdensus is recommended in those who meet the following criteria:

FDA-Approved Indication

1. **Asthma.** Approve Exdensus for the duration noted if the patient meets ONE of the following (A or B):
 - A) **Initial Therapy.** Approve for 6 months if the patient meets ALL of the following (i, ii, iii, iv, and v):
 - i. Patient is ≥ 12 years of age; AND
 - ii. Patient meets ONE of the following (a or b):
 - a) Patient has a blood eosinophil level ≥ 150 cells per microliter within the previous 6 weeks; OR
 - b) Patient had a blood eosinophil level ≥ 150 cells per microliter prior to treatment with Exdensus or another monoclonal antibody therapy that may alter blood eosinophil levels; AND

Note: Examples of monoclonal antibody therapies that may alter blood eosinophil levels include Exdensus, Adbry (tralokinumab-ldrm subcutaneous injection), Cinqair (reslizumab intravenous infusion), Dupixent (dupilumab subcutaneous injection), Ebglyss (lebrikizumab-lbkz subcutaneous injection), Fasenra (benralizumab subcutaneous injection), Nemluvio (nemolizumab-ilto subcutaneous injection), Nucala (mepolizumab subcutaneous injection), Tezspire (tezepelumab-ekko subcutaneous injection), Xolair (omalizumab subcutaneous injection).
 - iii. Patient has received at least 3 consecutive months of combination therapy with BOTH of the following (a and b):
 - a) An inhaled corticosteroid; AND
 - b) At least one additional asthma controller or asthma maintenance medication; AND

Note: Examples of additional asthma controller or asthma maintenance medications are inhaled long-acting beta₂-agonists, inhaled long-acting muscarinic antagonists, and monoclonal antibody therapies for asthma (e.g., Cinqair, Dupixent, Exdensus, Fasenra, Nucala, Tezspire, and Xolair). Use of a combination inhaler containing both an inhaled corticosteroid and additional asthma controller/maintenance medication(s) would fulfill the requirement for both criteria a and b.
 - iv. Patient has asthma that is uncontrolled or was uncontrolled at baseline as defined by ONE of the following (a, b, c, d, or e):

Note: “Baseline” is defined as prior to receiving Exdensus or another monoclonal antibody therapy for asthma. Examples of monoclonal antibody therapies for asthma include Cinqair, Dupixent, Exdensus, Fasenra, Nucala, Tezspire, and Xolair.

- a) Patient experienced two or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year; OR
 - b) Patient experienced one or more asthma exacerbation(s) requiring a hospitalization, an emergency department visit, or an urgent care visit in the previous year; OR
 - c) Patient has a forced expiratory volume in 1 second (FEV₁) < 80% predicted; OR
 - d) Patient has an FEV₁/forced vital capacity (FVC) < 0.80; OR
 - e) Patient has asthma that worsens upon tapering of oral (systemic) corticosteroid therapy; AND
 - v. The medication is prescribed by or in consultation with an allergist, immunologist, or pulmonologist; OR
- B) Patient is Currently Receiving Exdensur.** Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):
- i. Patient has already received at least 6 months of therapy with Exdensur; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy with Exdensur should be considered under criterion 1A (Asthma, Initial Therapy).
 - ii. Patient continues to receive therapy with one inhaled corticosteroid or one inhaled corticosteroid-containing combination inhaler; AND
 - iii. According to the prescriber, the patient has responded to therapy.
Note: Examples of a response to Exdensur therapy are decreased asthma exacerbations; decreased asthma symptoms; decreased hospitalizations, emergency department, urgent care, or medical clinic visits due to asthma; and decreased requirement for oral corticosteroid therapy.

Dosing. Approve up to 100 mg given subcutaneously once every 6 months.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Exdensur is not recommended in the following situations:

1. **Concurrent use of Exdensur with another Monoclonal Antibody Therapy.** The efficacy and safety of Exdensur used in combination with other monoclonal antibody therapies have not been established.
Note: Monoclonal antibody therapies are Adbry® (tralokinumab-ldrm subcutaneous injection), Cinqair® (reslizumab intravenous injection), Dupixent® (dupilumab subcutaneous injection), Ebglyss® (lebrikizumab-lbkz subcutaneous injection), Fasenra® (benralizumab subcutaneous injection), Nemluvio® (nemolizumab-ilto subcutaneous injection), Nucala® (mepolizumab subcutaneous injection), Tezspire® (tezepelumab-ekko subcutaneous injection), or Xolair® (omalizumab subcutaneous injection).
2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Exdensus subcutaneous injection [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2025.
2. Jackson DJ, Wechsler ME, Jackson, DJ, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. *N Engl J Med*. 2024;391:2337-2349.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated November 15, 2025. Available at: <http://www.ginasthma.org>. Accessed on December 22, 2025.
4. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014;43:343-373.
5. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society Guideline. *Eur Respir J*. 2020;55:1900588.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	12/30/2025